July 10, 2018

Symphogen A/S and Selexis Expand Relationship as Symphogen Advances its Monoclonal Antibody (mAb) Mixture Pipeline

Read More
June 12, 2018

ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer’s Disease

Read More
May 31, 2018

IAVI, Selexis SA and Collaborators Publish Study Highlighting Improved Approach for Generating Complex Proteins Required for Producing HIV Vaccines

Read More
May 17, 2018

Selexis Named One of the “Best Companies to Work for in Switzerland 2018”

Read More
May 07, 2018

Swiss Biotech Association Honors Selexis Among Its Inaugural Group of Swiss Biotech Success Stories

Read More